This is Archived Content

This content is available for historical purposes only. It may not reflect the current state of science or language from the National Institute on Drug Abuse (NIDA).
View current meetings on


September 1, 2015 - 9:00am to 10:00am


Holly Buchanan

CDR Christopher Jones, PharmD, MPH, serves as senior advisor in the Office of Public Health Strategy and Analysis in the Office of the Commissioner at the U.S. Food and Drug Administration (FDA). In this role, he works on a variety of priority public health issues facing FDA and conducts research to better understand the health impacts of FDA’s regulatory actions. Prior to joining FDA, Dr. Jones was as a lead subject matter expert on prescription drug overdose at the Centers for Disease Control and Prevention (CDC). His CDC work focused on strategic policy development and implementation, engaging national and state partners, and conducting research to improve policy and clinical practice. Prior to CDC, Dr. Jones completed a detail to the White House Office of National Drug Control Policy (ONDCP) as Senior Public Health Advisor. During his detail, he co-led the development of the administration’s Prescription Drug Abuse Prevention Plan released in April 2011. Chris previously worked in the FDA’s Center for Drug Evaluation and Research and in the CDC’s Strategic National Stockpile.